Secondary hyperparathyroidism (SHPT) is a medical condition in which parathyroid hormone (PTH) is produced in excess by parathyroid glands in response to hypocalcemia the condition where blood calcium level is low. This condition mainly occurs in patients with kidney failure. Failing kidneys are unable to convert Vitamin A to its active form as they do not adequately excrete phosphate resulting in the formation of insoluble calcium phosphate by the body thus, leading to secondary hyperparathyroidism. Bone and joint pain, as well as limb deformities, are some of the major symptoms of secondary hyperparathyroidism (SHPT). Treatment for SHPT involves surgical operation or consumption of prescribed drugs that help to maintain the level of parathyroid hormone, calcium, and phosphorus within the accepted targeted areas. According to the U.S. Food & Drug Administration (FDA) 2012, Secondary hyperparathyroidism is a serious chronic condition that affects a high percentage of patients receiving kidney dialysis. In the case of prognosis, if the SHPT is left untreated, the disease can lead to tertiary hyperparathyroidism and is then associated with hypercalcemia. According to the National Institute of Diabetes & Digestive & Kidney Diseases, the two prime reasons resulting in chronic kidney disease are diabetes and high blood pressure. Patients suffering from CKD, due to one of the reasons, if remain undetected can progress to irreversible kidney failure.
Request Free PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1570
The growing incidence of chronic kidney diseases is one of the prime factors fueling the market growth of the global secondary hyperparathyroidism treatment market. According to the Centers for Disease Control & Prevention (CDC) 2017, 30 million people or 15% of the U.S. adults are estimated to have chronic kidney disease, out of which 48% suffer severely with reduced kidney function, however, they are not aware of having a CKD. Moreover, according to the National Kidney Foundation 2016, 10% of the population across the world are affected with chronic kidney diseases. In addition to this, growing research in the field of nephrology to develop new drugs and therapies for the treatment of secondary hyperparathyroidism is also expected to fuel market growth. For instance, Sanofi SA’s Hectorol capsules are undergoing Phase 3 clinical trials to evaluate the safety and efficacy of this medication in reducing the level of secondary hyperparathyroidism in pediatric patients with chronic kidney diseases at stage 3 and 4. The drug is expected to complete its study in December 2017, and be commercially available in the market. On the other side, side effects associated with secondary hyperparathyroidism treatment such as muscle spasm, diarrhea, and vomiting are projected to curb the growth of the market.
Based on region, the global secondary hyperparathyroidism treatment market by Coherent Market Insights is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the global secondary hyperparathyroidism treatment market, and this can be attributed to increasing research and development of novel therapies and potential drugs for secondary hyperparathyroidism as well as a high prevalence of chronic kidney disease. According to the Centers for Disease Control & Prevention (CDC), in 2014, 118,000 people in the U.S. started treatment for ESRD, and 662,000 were living on chronic dialysis. Furthermore, Europe is expected to be the second-largest contributor in the secondary hyperparathyroidism treatment market, in terms of revenue and is projected to gain significant traction in the near future owing to launch of new drugs and therapies, to combat secondary hyperparathyroidism as well as the presence of significant population suffering from the disease in this region. For instance, in December 2016, Amgen’s drug etecalcetide (Parsabiv), received marketing approval in Europe by the European Commission for treatment of secondary hyperparathyroidism in adult patients with chronic kidney diseases. Furthermore, Asia Pacific is projected to be the fastest-growing region, and this can be attributed to the rising number of clinical trials by regional companies for the launch of new drugs. For instance, Kyowa Hakko Kirin China Pharmaceutical Co., Ltd is under Phase 4 clinical trial to determine the safety and efficacy of its new lead compound Cinacalet for treatment of patients suffering from mild to moderate SHPT and expected to be launched in the market by April 2019.
Key players operating in the global secondary hyperparathyroidism treatment market include AbbVie, Inc., Shire, Inc., OPKO Health, Amgen, Inc., Sanofi SA, F. Hoffmann-La Roche AG, Kyowa Hakko Kirin Co. Ltd., KAI Pharmaceuticals, Astellas Pharma, Inc., Deltanoid Pharmaceuticals, and Leo Pharma. Major players are focusing on innovation and new product development, to maintain their position in the market and enhance their share. For instance, in June 2016, OPKO Health introduced Rayaldee (calcifediol) for the treatment of SHPT in adults with stage 3 or 4 of chronic kidney disease.
Purchase a copy of Secondary Hyperparathyroidism Treatment Market Report: https://www.coherentmarketinsights.com/insight/buy-now/1570
The global secondary hyperparathyroidism treatment market by Coherent Market Insights is segmented on the basis of drug class and distribution channels.
On the basis of drug class
- Vitamin D Derivatives
- Phosphate Binders
- Calcium-Based Binders
- Non-Calcium Based Binders
Based on the distribution channel
- Hospital Pharmacies
- Retail Pharmacies
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Name: Mr. Raj Shah
Phone: US +12067016702 / UK +4402081334027